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Abstract
Neuroplasticity is fundamental for brain functions, abnormal changes of which are associated with mood disorders and cognitive impairment.
Neuroplasticity can be affected by neuroactive medications and by aging. Vortioxetine, a multimodal antidepressant, has shown positive effects on
cognitive functions in both pre-clinical and clinical studies. In rodent studies, vortioxetine increases glutamate neurotransmission, promotes dendritic
branching and spine maturation, and elevates hippocampal expression of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1) at the
transcript level. The present study aims to assess the effects of vortioxetine on several neuroplasticity-related molecules in different experimental
systems. Chronic (1 month) vortioxetine increased Arc/Arg3.1 protein levels in the cortical synaptosomes of young and middle-aged mice. In young
mice, this was accompanied by an increase in actin-depolymerizing factor (ADF)/cofilin serine 3 phosphorylation without altering the total ADF/cofilin
protein level, and an increase in the GluA1 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor phosphorylation
at serine 845 (S845) without altering serine 831 (S831) GluA1 phosphorylation nor the total GluA1 protein level. Similar effects were detected in
cultured rat hippocampal neurons: Acute vortioxetine increased S845 GluA1 phosphorylation without changing S831 GluA1 phosphorylation or the total
GluA1 protein level. These changes were accompanied by an increase in α subunit of Ca2+/calmodulin-dependent kinase (CaMKIIα) phosphorylation (at
threonine 286) without changing the total CaMKIIα protein level in cultured neurons. In addition, chronic (1 month) vortioxetine, but not fluoxetine,
restored the age-associated reduction in Arc/Arg3.1 and c-Fos transcripts in the frontal cortex of middle-aged mice. Taken together, these results
demonstrated that vortioxetine modulates molecular targets that are related to neuroplasticity.
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Introduction
Neuroplasticity is critical for brain functions. In addition to
affecting learning and memory, neuroplasticity changes are also
associated with the pathophysiology of affective disorders such
as depression, and with the mechanisms of actions of antidepressants (Hayley and Litteljohn, 2013). Vortioxetine is an antidepressant with a multimodal mechanism of action, directly
modulating several serotonin (5-HT) receptors (an agonist of the
5-HT1A receptor, a partial agonist of the 5-HT1B receptor; an
antagonist of the 5-HT1D, 5-HT3, and 5-HT7 receptors) in addition to inhibiting the serotonin transporter (Mork et al., 2012).
Clinical studies in patients with major depressive disorder show
that vortioxetine improves depressed mood, as well as some
aspects of cognitive function (Katona et al., 2012; McIntyre
et al., 2014; Mahableshwarkar et al., 2015; Sanchez et al., 2015).
Similarly, in preclinical animal models vortioxetine has demonstrated antidepressant-like and pro-cognitive effects (Guilloux
et al., 2013; Li et al., 2013, 2015a; Mork et al., 2012). Therefore,
it is plausible that vortioxetine may induce neuroplastic changes.
Several preclinical studies provide evidence that modulation
of neuroplasticity is part of the underlying mechanisms for vortioxetine. Direct receptor activities of vortioxetine (antagonism of
the 5-HT3 receptor in particular) inhibits gamma amino-butyric

acid (GABA)ergic interneurons and thereby disinhibit neurotransmission, including that of glutamate (Riga et al., 2013,
2014). Vortioxetine also regulates functional plasticity (including
long-term potentiation (LTP)) (Betry et al., 2015; Dale et al.,
2014) and structural plasticity (such as dendritic branching and
spine morphology) (Chen et al., 2016; Waller et al., 2015).
Furthermore, in middle-aged mice and young adult rats, vortioxetine increases the expression of genes related to neuroplasticity
at the transcript level in the hippocampus and prefrontal cortex,
respectively (Du Jardin et al., 2013; Li et al., 2015a); however,
the effects of vortioxetine on molecules involved in the regulation of neuroplasticity have so far not been examined in greater
detail at the protein level.
Several factors were taken into consideration for the present
study. Female mice were chosen for in vivo experiments, to
address the need for preclinical studies in this under-studied
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population and to avoid stress-induced neuroplasticity changes
(Li et al., 2015b) that result from fighting, which is more common among group-housed males. Considering that neuroplasticity is affected by aging, it is possible that age-associated
differences may exist in neuroplastic responses to drug treatment.
Therefore, we included young and middle-aged mice, as well as
embryonic neuronal cultures, in the current study.
Given that the frontal cortex is essential for cognitive and
affective functions, we investigated changes in neuroplasticity
markers both in cortical tissue samples and in hippocampal neuronal cultures. Furthermore, we focused on activity-regulated
cytoskeleton-associated protein (Arc/Arg3.1), actin-depolymerizing factor (ADF)/cofilin, the GluA1 subunit of the α-amino3-hydroxy-5-methyl-4-isoxazolepropionic
acid
(AMPA)
receptor, and the Ca2+/calmodulin-dependent kinase (CaMKII),
as these molecules are indicted in functional and structural plasticity. To examine whether the effects of vortioxetine on neuroplasticity are related to the multimodal mechanism of action,
we compared the effects of chronic vortioxetine and fluoxetine
(a selective serotonin reuptake inhibitor (SSRI)) on the mRNA
levels of genes in the frontal cortex of middle-aged mice. In
addition to the same targets that were examined at the protein
level (Arc/Arg3.1, Gria1 and Camk2a), we measured another
molecular marker for neuronal activity, Fos. Because the
expression of both Arc/Arg3.1 and Fos are under the control of
the transcription factor cAMP response element-binding protein (CREB), similar changes in the expression of both genes
may provide stronger evidence for activation of the relevant
signaling cascades.
Arc/Arg3.1 is an immediate early gene involved in the regulation of neuroplasticity, and in the consolidation of learning and
memory (Bramham et al., 2010; Li et al., 2015b). Arc/Arg3.1
may regulate neuroplasticity at different levels, such as glutamate
receptor trafficking, cytoskeleton remodeling and neuronal firing, as well as LTP and LTD (long-term depression) (Bramham
et al., 2010; Ren et al., 2014). Vortioxetine reverses the age-associated reduction in hippocampal Arc/Arg3.1 mRNA level in middle-aged mice, which is accompanied by improved performance
in a hippocampal-dependent behavioral task (Li et al., 2015a). It
is not clear whether this effect can also be detected at the protein
level, in other brain regions, or in animals of different ages.
Hence, the present study assessed the effects of chronic vortioxetine treatment on the levels of Arc/Arg3.1 mRNA and protein in
the frontal cortex of young and middle-aged mice.
Structural neuroplasticity can be regulated by ADF/cofilin, a
family of actin depolymerizing factors. ADF/cofilin controls
actin turnover, which is a process important for dendrites and
spine remodeling (Rust, 2015), as well as for LTP and LTD
(Fukazawa et al., 2003; Zhou et al., 2004). Dysregulation of
ADF/cofilin has been linked to disruptions of memory (Wang
et al., 2013; Zimmermann et al., 2015) and to neurodegenerative
or neurodevelopmental disorders (Bamburg et al., 2010; Barone
et al., 2014; Zimmermann et al., 2015). Phosphorylation at serine
3 (S3) inactivates ADF/cofilin (Yang et al., 1998) and promotes
actin polymerization, which can be regulated by Arc/Arg3.1
(Messaoudi et al., 2007). Here we assess the effects of chronic
vortioxetine treatment on the protein levels of total ADF/cofilin
and its phosphorylation in cortical tissue from young and middleaged mice. The antibodies used in this study recognize all members of the ADF/cofilin family.
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The AMPA receptor (AMPAR) is essential for glutamate neurotransmission-induced neuroplasticity (Bassani et al., 2013) and
for learning and memory (Kessels and Malinow, 2009).
Phosphorylation of the AMPAR subunit GluA1 at serine 831
(S831), by CaMKII or protein kinase C and serine 845 (S845, by
PKA) residues can alter the localization, conductance and open
probability of GluA1-containing AMPAR (Banke et al., 2000;
Derkach et al., 1999; Hayashi et al., 2000), thereby regulating
neuroplasticity. In addition, Arc/Arg3.1 modulates the trafficking
of AMPARs by upregulating their endocytosis (Byers et al.,
2015; Chowdhury et al., 2006). Even though vortioxetine
increases LTP in the in vitro electrophysiology studies done in
hippocampus slices (Dale et al., 2014), it is not clear whether it
modulates the expression or phosphorylation of GluA1. In the
present study, we therefore investigated the effects of chronic
vortioxetine treatment on the levels of total GluA1, S831 and
S845 GluA1 phosphorylation in the cortex of young and middleaged mice, as well as the effects of acute vortioxetine treatment
on these measures in cultured neurons.
Kinase CaMKII is critical for neuroplasticity processes such
as LTP (Lisman et al., 2012; Shonesy et al., 2014). A significant
increase in CaMKII autophosphorylation was detected following
induction of LTP in the hippocampal CA1 region (Fukunaga,
1993), and may be considered as a marker for CaMKII activation
(Shonesy et al., 2014). Activation of CaMKII is essential for the
cognitive enhancer nefiracetam to potentiate AMPAR-mediated
LTP (Moriguchi et al., 2008). In the present study, we therefore
investigated the effects of vortioxetine on CaMKII autophosphorylation at threonine 286 (T286) and the total CaMKII levels in a
primary hippocampal neuronal culture system.

Methods
Animals
Chronic drug effects were measured in young adult (3 months of
age) or middle-aged (12 months of age) female C57BL/6 mice
(Charles River, Wilmington, MA, USA) housed three per cage.
In addition, acute drug effects were measured in cultured hippocampal neurons obtained from singly housed pregnant
Sprague-Dawley rat dams (Charles River, Wilmington, MA,
USA) on embryonic day 18 (E18). These animals were acclimatized under controlled environmental conditions (22 ± 2 °C; with
lights on from 06:00 to 18:00 h) with ad libitum access to water
and food for 1 week prior to the drug treatments or tissue collection. All animal experiments were carried out in accordance to
the Institutional Animal Care and Use Committee of Lundbeck
Research, following the US National Institute of Health (NIH)
and Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) guidelines.

Study design
The chronic effects of vortioxetine on Arc/Arg3.1, cofilin and
GluA1 were first examined in the frontal cortical homogenates
from both young (3 months old) and middle-aged (12 months
old) female mice, after 1 month of treatment (n = 5 to 6 mice per
group). The effects of acute vortioxetine (1 h exposure) on GluA1
and CaMKII proteins were examined in cultured rat hippocampal
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neurons (n = 3 independent experiments). Finally, the effects of
chronic vortioxetine and fluoxetine on the transcript levels of
Arc/Arg3.1, Fos, Gria1 (coding for GluA1) and Camk2a (coding
for CaMKIIα) were compared in frontal cortical homogenates
from middle-aged (12 months old) female mice after 1 month of
treatment. Vehicle-treated young adult (3 months old) female
mice were included as an age control (n = 10 mice per group).

In vivo drug treatment and sample collection
For the chronic experiments, mice were randomly assigned to
different groups and received 1 month of treatment. For the vehicle group, mice were fed with Purina 5001 rodent chow and plain
tap water. The vortioxetine group was fed with Purina 5001 chow
containing 600 mg vortioxetine/kg of food, and plain tap water.
The fluoxetine group received Purina 5001 chow and tap water
containing 147 mg fluoxetine/L water. Food pellets were prepared by Research Diets Inc. (New Brunswick, NJ). Compounds
were synthesized by Lundbeck A/S (Valby, Denmark). The doses
of vortioxetine and fluoxetine used had previously been shown to
fully occupy the serotonin transporter (using ex vivo autoradiography) and had demonstrated behavioral and molecular effects
(Li et al., 2015a). After 1 month of drug administration, the animals were euthanized and their frontal cortices quickly dissected.
The left cortices were stored in Ambion RNAlater® reagent
(Thermo Fisher Scientific, Waltham, MA, USA) at −20 °C for
mRNA analysis, and the right cortices were snap frozen and
stored at −80 °C for protein analysis.

Isolation, primary culture and drug
treatment of neurons
On embryonic day 18 (E18), pregnant dams were anesthetized
with CO2 and approximately 12 fetuses were obtained from each
rat. Whole brains were rapidly isolated from each fetus and their
hippocampi were dissected under a light microscope. Fetuses,
whole brains and dissected hippocampi were maintained in chilled
Hank’s balanced salt solution (HBSS, Gibco, Thermo Fisher
Scientific, Waltham, MA, USA) with 10 mM HEPES
(SigmaAldrich, Saint Louise, MO, USA) for the duration of the
dissection. Cells were dissociated from hippocampi using a papain
dissociation system (Worthington Biochemical Corporation,
Lakewood, NJ, USA) and resuspended in Neurobasal Media
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) containing 2% Invitrogen B27 supplement (Thermo Fisher Scientific,
Waltham, MA, USA) and 0.5 mM glutamine (100 × Glutamax,
Thermo Fisher Scientific, Waltham, MA, USA). Cell quantification was performed using a Cellometer Auto ×4 cell counter
(Nexcelom Biosciences, Lawrence, MA, USA), after which the
cells were plated into Corning 12-well poly-D-lysine-coated
plates (Sigma-Aldrich) at a density of 7.5 × 105 cells per well, in a
volume of 2 mL per well. Cells were incubated at 37°C in a
humidified atmosphere with 5% CO2/95% air, and their culture
media was refreshed every 4–5 days, for 21 days.
For the acute in vitro study, dissociated hippocampal cells
were treated with culture media containing 1 μM vortioxetine,
100 nM nefiracetam, or vehicle control (0.1% dimethyl sulfoxide (DMSO)) freshly prepared from a 10 mM stock solution for
1 h. Nefiracetam was chosen as a positive control, because it

activates CaMKII and increases CaMKIIα autophosphorylation.
The dosage of vortioxetine is similar to what was used in spine
morphology studies (Waller et al., 2015), and the dose of nefiracetam was chosen based on a previous report (Moriguchi
et al., 2008).

Synaptosome preparation from frontal
cortices
Crude synaptosomes were prepared as previously published (Li
et al., 2010), and synaptic proteins were confirmed to be enriched
in this preparation. Tissues were homogenized in lysis buffer
(0.32 M sucrose, 20 mM HEPES at pH 7.4, 1 mM EDTA, 1×
protease inhibitor cocktail (Sigma-Aldrich), and 1× phosphatase
inhibitor cocktail (Sigma-Aldrich)), using a Dounce homogenizer. Homogenates were separated by centrifugation for 15 min
at 2800 rcf at 4°C. The supernatant was further centrifuged at
12,000 rcf for 10 min at 4°C. The pellet from the second centrifugation was resuspended in buffer (50 mM Tris-HCl at pH 7.5,
150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate
(SDS), 2 mM EDTA, 1× protease inhibitor cocktail and 1× phosphatase inhibitor cocktail), and then sonicated using a VirSonic
60 ultrasonic cell disruptor (The Virtus Company, Inc. Gardiner,
NY, USA). The protein concentration of the resultant crude synaptosome was determined using the Micro BCA Protein Assay
Kit (Pierce, Thermo Fisher Scientific, Waltham, MA, USA).

Cell lysate preparation
Hippocampal cells from at least two wells that received the same
treatment were combined and lysed using an adjusted RIPA lysis
buffer (62.5 mM Tris-HCl at pH 6.8, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium orthovanadate,
1 mM EDTA, 1 mM EGTA, 200 mM DTT, 1 μg/mL phosphatase
inhibitor (Sigma-Aldrich), 1 μg/mL protease inhibitor cocktail
(Sigma-Aldrich), 2% SDS, 0.5% Triton X-100 and 10% glycerol).
Following centrifugation for 30 min at 16,000 rcf at 4°C, the supernatant was removed and aliquoted for further analysis. We measured the concentration of extracted proteins using the Pierce BCA
protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA).

Western blotting
Synaptosomal (40 µg) or cell lysate (20 µg) samples were separated by electrophoresis using Invitrogen NuPAGE® Novex®
4–12% Bis-Tris protein gels (Thermo Fisher Scientific, Waltham,
MA, USA) and transferred to nitrocellulose membranes, which
were first incubated with blocking buffer (Rockland
Immunochemicals Inc., Limerick, PA, USA) for 1 h at room temperature, followed by an overnight incubation with blocking
buffer containing primary antibodies at 4°C. Afterwards, the
membranes were thoroughly washed with PBS plus 0.1% Tween
20, and then incubated with blocking buffer containing fluorescent-labeled secondary antibodies, for 1 h at room temperature.
After additional washes in PBS buffer, the membranes were
scanned using the Li-COR Odyssey system (Li-COR Biosciences,
Lincoln, NE, USA). The densities of the target bands were measured using the accompanying software (Image Studio Lite 4.0,
Li-COR Biosciences, Lincoln, NE, USA). Membranes were
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Table 1. Information on antibodies used in Western blotting experiments.
Primary antibodies

Species

Dilutions

Sources

Arc/Arg3.1
GAPDH
Phospho-GluR1 (S831)
Phospho-GluR1 (S845)
GluR1
Phospho-Cofilin (S3)
Cofilin
Phospho-CaMKIIα (T286)
CaMKIIα
β-Actin

Rabbit
Rabbit
Rabbit
Rabbit
Mouse
Rabbit
Mouse
Rabbit
Mouse
Mouse

1:2000
1:20000
1:1000
1:1000
1:10000
1:750
1:750
1:2000
1:2000
1:100000

Custom-made polyclonal antibody against full-length murine protein (Biogenes, Berlin, Germany)
Sigma-Aldrich (Saint Louise, MO, USA) G9545
Millipore (Temecula, CA, USA) 04-823
Millipore (Temecula, CA, USA) 04-1073
Millipore (Temecula, CA, USA) MAB2263
Cell Signaling Technology (Danvers, MA, USA) 3311
Cell Signaling Technology (Danvers, MA, USA) 3318
Abcam (Cambridge, MA, USA) AB5683
Sigma-Aldrich (St. Louis, MO, USA) C265
Sigma-Aldrich (St. Louis, MO, USA) A2228

Secondary antibodies

Species

Dilutions

Sources

Anti-rabbit IRDye 680RD
Anti-mouse IRDye 680LT
Anti-rabbit IRDye 800CW
Anti-mouse IRDye 800CW

Goat
Goat
Goat
Goat

1:20000
1:20000
1:20000
1:20000

Li-Cor Biosciences (Lincoln, NE, USA) 925-68071
Li-Cor Biosciences (Lincoln, NE, USA) 925-68020
Li-Cor Biosciences (Lincoln, NE, USA) 925-32211
Li-Cor Biosciences (Lincoln, NE, USA) 925-32210

stripped (RevitablotTM Western Blot Stripping Buffer, Rockland
Immunochemicals Inc., Limerick, PA, USA) and re-probed for
different targets. The antibody information is listed in Table 1.
We calculated the levels of phosphorylated GluA1 (p-S845
GluA1 and p-S831 GluA1), ADF/cofilin (p-S3 ADF/cofilin) and
CaMKIIα (p-T286 CaMKIIα) as proportions of total GluA1,
ADF/cofilin, or CaMKIIα, respectively. The levels of total protein of GluA1, ADF/cofilin and CaMKIIα were calculated relative to GAPDH or β-actin levels. In order to compare samples
run on different gels, a common synaptosomal sample was
included in every gel and used as a quantitative control. The raw
signals were first standardized to the quantitative control, and
then expressed as fold changes, relative to vehicle-treated young
animals (Figures 1B, 2 and 3) or vehicle-treated neuronal cultures (Figure 4).

Gene expression analysis using quantitative
RT-PCR
Transcript level gene expression was measured using quantitative RT-PCR, as previously described (Li et al., 2015a). RNA was
isolated from tissue homogenates using a RNAqueous® kit
(Ambion, Thermo Fisher Scientific, Waltham, MA, USA) and
mRNA was enriched by removing genomic DNA with a DNase
digestion step. RNA concentration and quality were determined
using an Agilent Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA). Reverse transcription of mRNA to cDNA was accomplished using Superscript II™ and random hexamers (Thermo
Fisher Scientific, Waltham, MA, USA). Reactions were performed in duplicate using 600 ng of RNA in each reaction and
then the products were pooled. Concentrations of cDNA were
quantified using a dye intercalation assay (Quant-iT™ OliGreen®
ssDNA Assay Kit, Thermo Fisher Scientific, Waltham, MA,
USA). SensiFAST™ Probe Hi-Rox mix (Bioline, Taunton, MA),
gene specific probe and primers (Thermo Fisher Scientific,
Waltham, MA, USA), and 2 ng of cDNA were mixed and total
volumes were adjusted to 20 μL. All qPCR reactions were performed in duplicate on 384-well plates using an Applied
Biosystems 7900HT Fast Real-Time PCR System (Thermo

Fisher Scientific, Waltham, MA, USA). Normalization of raw
qPCR signals was performed using the geometric mean of a
panel of house-keeping genes (B2m, Ppia, Gapdh, Rplp0, Rpl13a,
Tbp, Ubc) that were selected for their stable expression based on
the geNorm algorithm (Vandesompele et al., 2002). No significant change in the expression levels of housekeeping genes was
found between different groups. The relative expression level of
each target was calculated using the comparative threshold cycle
(CT) method, with the expression level of vehicle-treated young
mice (Figure 1A) or vehicle-treated middle-aged mice (Figure 5)
defined as 100.

Statistical analysis
Results are expressed as the mean ± the standard error (SE).
Statistical analyses were performed using JMP (SAS, Cary, NC,
USA) or Prism (GraphPad, La Jolla, CA, USA) software. Twoway ANOVA (with age and treatment as two independent factors)
followed by post-hoc Tukey-Kramer tests (Figure 1, Figure 2 and
Figure 3), or one-way ANOVA followed by post-hoc Dunnett’s
methods (Figure 4 and Figure 5) were used. Significant levels
were defined as p < 0.05.

Results
In vivo effects of chronic vortioxetine in
young and middle-aged mice
Young and middle-aged mice were treated with vortioxetine for 1
month. The expression of the immediate early gene Arc/Arg3.1
(both at the transcript and protein levels) and several other
molecular targets associated with Arc/Arg3.1 and neuroplasticity
(both at total protein levels and phosphorylated protein levels)
were measured in cortical tissues.
Arc/Arg3.1 expression was measured at the transcript level
using quantitative RT-PCR (Figure 1A); and at the protein
level, using Western blotting (Figure 1B). There was a significant
overall difference in Arc/Arg3.1 transcript levels (Figure 1A;
F(3,20) = 10.70; n = 6 per group; p < 0.05); with significant age
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Figure 1. Arc/Arg3.1 expression in the mouse frontal cortex. Arc/Arg3.1
expression at the transcript level was determined using quantitative
RT-PCR (A). Vortioxetine significantly increased Arc/Arg3.1 mRNA levels
in the frontal cortex of young mice. The increase after vortioxetine
treatment did not reach significant levels in the middle-aged mice. Arc/
Arg3.1 expression was also examined at the protein level, using Western
blotting of synaptosome preparations (B). Vortioxetine significantly
increased Arc/Arg3.1 protein levels in the frontal cortex of both young
and middle-aged mice (n = 6 per group), 2-way ANOVA followed by
Tukey-Kramer post-hoc tests.

Figure 2. ADF/cofilin protein level and phosphorylation status in
synaptosomal preparations from mouse frontal cortex. Total ADF/cofilin
and phosphorylated cofilin were examined using Western blotting.
Representative blot images are shown (A). VOR significantly increased
the phosphorylation of ADF/cofilin (p-S3 ADF/cofilin-1/total ADF/
cofilin-1) in young, but not in middle-aged, mice (B). There was no
significant difference in total ADF/cofilin levels (C). n = 5–6 per group.
Two-way ANOVA followed by Tukey-Kramer post-hoc tests.
< 0.05 compared to VEH treatment.
< 0.05 compared to young mice that received the same treatment.
ADF: actin depolymerizing factor; ANOVA: analysis of variance; VEH: vehicle; VOR:
vortioxetine.

ap

< 0.05 compared to vehicle treatment.
< 0.05 compared to young mice that received the same treatment.
ANOVA: analysis of variance; mRNA: messenger ribonucleic acid; RT-PCR: reverse
transcriptase polymerase chain reaction; VEH: vehicle; VOR: vortioxetine.

ap

bp

bp

(F(1,20) = 7.95; p < 0.05) and vortioxetine treatment (F(1,20) =
22.58; p < 0.01) effects. There was no significant interaction
between these two factors, indicating the vortioxetine effect was
similar in both age groups. Post-hoc analysis demonstrated that
vortioxetine significantly increased the Arc/Arg3.1 mRNA levels
in young mice, while the increase in middle-aged mice did not
reach significance (p = 0.09). The Arc/Arg3.1 level in young
mice treated with vortioxetine was significantly higher than in
middle-aged mice that received vortioxetine treatment. At the
protein level (Figure 1B), there was a significant overall difference (F(3,20) = 7.29; n = 6 per group; p < 0.05), with treatment
effect being significant (F(1,20) = 21.49; p < 0.05). There was no
significant age effect or significant interaction between these two
factors. Post-hoc analysis indicated that vortioxetine significantly increased Arc/Arg3.1 protein levels in the cortical synaptosomes of both young and middle-aged mice.
Total and phosphorylated ADF/cofilin (at S3 residue, p-S3
ADF/cofilin) levels in cortical synaptosomes were measured
using Western blotting (Figure 2). There was a significant overall

difference in the proportion of ADF/cofilin that was phosphorylated at residue S3 (p-S3 ADF/cofilin/total ADF/cofilin; F(3,19) =
13.31; n = 5 to 6 per group; p < 0.05; Figure 2B). Both the age
effect (F(1,19) = 31.95; p < 0.05) and the interaction between age
and treatment (F(1,19) = 8.69; p < 0.05) were significant. Post-hoc
analysis indicated that vortioxetine significantly increased ADF/
cofilin phosphorylation in young mice. Young mice that received
vortioxetine treatment also had a significantly higher proportion
of ADF/cofilin that was phosphorylated than the middle-aged
mice treated with vortioxetine. On the other hand, there was no
significant difference in total ADF/cofilin levels (F(3,19) = 1.69; n
= 5 to 6 per group; Figure 2C).
The total and phosphorylated GluA1 protein levels in cortical
synaptosomes were also measured using Western blotting (Figure 3).
There was a significant difference in the proportion of the GluA1
protein that was phosphorylated at S845 (p-S845 GluA1/total
GluA1; F(3,20) = 23.03; n = 6 per group; p < 0.05; Figure 3B), with
significant effects of age (F(1,20) = 36.47; p < 0.05), vortioxetine
treatment (F(1,20) = 24.83; p < 0.05), and the interaction between
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Figure 3. AMPA receptor subunit GluA1 protein level and phosphorylation status in synaptosome preparations from mouse frontal cortex. Total
and phosphorylated GluA1 levels were measured using Western blotting of synaptosome preparations (A). Vortioxetine induced an increase in S845
GluA1 phosphorylation (p-S845 GluA1/total GluA1) in young, but not in middle-aged, mice (B). Neither age nor vortioxetine treatment significantly
changed the level of S831 GluA1 phosphorylation (p-S831 GluA1/total GluA1, C). Middle-aged mice had significantly lower levels of the GluA1
subunit, and vortioxetine treatment had no effect (D). N = 6 per group; 2-way ANOVA followed by Tukey-Kramer post-hoc tests.
< 0.05 compared to VEH treatment;
< 0.05 compared to young mice that received the same treatment.
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANOVA: analysis of variance; VEH: vehicle; VOR: vortioxetine.
ap
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these two factors (F(1,20) = 7.78; p < 0.05). Post-hoc analysis indicated that vortioxetine induced a significant increase in the S845
GluA1 phosphorylation in young mice. Young mice treated with vortioxetine also had significantly higher S845 GluA1 phosphorylation
than middle-aged mice that received vortioxetine treatment. In contrast, there was no overall significant difference in the proportion of
GluA1 that was phosphorylated at the S831 residue (p-S831 GluA1/
total GluA1; n = 6 per group; F(3,20) = 2.39; p = 0.1; Figure 3C).
Lastly, there was a significant difference in total GluA1 levels (F(3,20)
= 11.42; n = 6 per group; p < 0.05; Figure 3D), with a significant age
effect (F(1,20) = 32.97; p < 0.05), but no vortioxetine effect or interaction between these two factors. Post-hoc analysis demonstrated that
middle-aged mice had significantly lower levels of total GluA1 protein in both the vehicle-treated and vortioxetine-treated groups.

In vitro effects of acute vortioxetine in
hippocampal neuronal cultures
To further address whether the effects of vortioxetine are mediated by CaMKII, we examined the acute effect of vortioxetine
along with a positive control, nefiracetam, on the phosphorylation and total levels of CaMKIIα and GluA1 in an in vitro system
(Figure 4).
There was a significant overall difference in the proportion of
CaMKIIα that is phosphorylated at the T286 residue (p-T286
CaMKIIα/total CaMKIIα) following the drug treatments (F(2,6) =
8.871; n = 3; p < 0.05; Figure 4B). Post-hoc analysis indicated

that both vortioxetine (1 μM) and nefiracetam (100 nM) significantly increased T286 CaMKIIα phosphorylation relative to
vehicle (0.1% DMSO) treatment. On the other hand, there was no
significant difference in total CaMKIIα protein level after the
drug treatments (Figure 4C).
There was a significant overall difference in S845 GluA1
phosphorylation (p-S845 GluA1/total GluA1; F(2,6) = 16.41;
n = 3; p < 0.05; Figure 4D). Post-hoc analysis indicated that vortioxetine, but not nefiracetam, significantly increased S845
GluA1 phosphorylation. On the other hand, S831 GluA1 phosphorylation (p-S831 GluA1/total GluA1; Figure 4E); and total
GluA1 (Figure 4F) were not affected by these drug treatments.

Comparison of chronic vortioxetine and
fluoxetine with respect to cortical gene
expression in middle-aged mice
In a separate, larger cohort (10 mice per group) of middle-aged
female mice, we measured the effects of chronic vortioxetine
and fluoxetine on mRNA levels of several of the targets examined in the present study (Arc/Arg3.1, Camk2a coding for
CamKIIα, Gria1 coding for GluA1) and Fos (coding for c-Fos,
a molecular marker for neuronal activity). Vehicle-treated young
mice were included as an age control. There was a significant
overall difference in Arc/Arg3.1 transcript levels (F(3,36) = 6.25;
p < 0.05; Figure 5A). Post-hoc analysis indicated that middleaged mice had significantly lower levels of Arc/Arg3.1 mRNA
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Figure 4. Total levels and phosphorylation status of CaMKIIα and GluA1 in dissociated embryonic hippocampal neurons. Total and phosphorylated
CaMKIIα and GluA1 levels were measured in cell lysates obtained from cultured hippocampal neurons using Western blotting (A). Both NEF
and vortioxetine significantly increased CaMKIIα phosphorylation at T286 (p-T286 CaMKIIα/total CaMKIIα, B). There was no change in total
CaMKIIα protein level (C). VOR, but not NEF, significantly increased S845 GluA1 phosphorylation (p-S845 GluA1/total GluA1, D). S831 GluA1
phosphorylation (p-S831 GluA1/total GluA1, E) and total GluA1 (F) were not changed by drug treatments. Results are summarized from three
independent experiments. One-way ANOVA followed by Dunnett’s comparison.
ap < 0.05 compared to vehicle treatment.
ANOVA: analysis of variance; NEF: nefiracetam; VEH: vehicle; VOR: vortioxetine.

when compared to young mice. Vortioxetine, but not fluoxetine,
significantly increased Arc/Arg3.1 mRNA levels in the middleaged mice. There was also a significant overall difference in the
mRNA levels of another immediate early gene, Fos (F(3,36) =
7.83; p < 0.05; Figure 5B). Post-hoc analysis indicated that middle-aged mice had significantly lower levels of Fos mRNA,
compared to young mice. Vortioxetine, but not fluoxetine,
reversed this age-associated reduction in Fos mRNA levels. On
the other hand, there was no significant difference in mRNA
levels of the GluA1 subunit of the AMPA receptor (Gria1,
Figure 5C), nor CaMKIIα (Camk2a, Figure 5D).

Discussion
In the present study, molecular changes following vortioxetine
treatment were examined in murine cortical tissue in vivo and in rat
embryonic hippocampal neuronal cultures, in vitro. Vortioxetine
increased cortical expression of the immediate early genes Arc/
Arg3.1 (at both the transcript and protein levels) and Fos (at the
transcript level). Vortioxetine also increased phosphorylation of
CaMKIIα (in vitro), ADF/cofilin (in vivo), and the GluA1 subunit
of the AMPA receptor (both in vivo and in vitro). Taken together,
these findings support the hypothesis that vortioxetine increases
moieties and processes involved in synaptic plasticity and suggest
several possible directions for future studies.
Increased Arc/Arg3.1 expression following chronic vortioxetine treatment was detected in different brain regions in mice of

different ages (current and earlier studies by Li et al., 2015a). This
may result from increased glutamate neurotransmission (Bramham
et al., 2010; Morin et al., 2015), which is achieved by vortioxetine
(Betry et al., 2015; Dale et al., 2014; Riga et al., 2013). In addition, direct modulation of other G-protein coupled 5-HT receptors
(Li et al., 2015b) may also contribute to this effect of vortioxetine.
Consistent with its key role in neuroplasticity (Bramham et al.,
2008), upregulation of Arc/Arg3.1 expression may be associated
with other molecular changes induced by vortioxetine.
Increasing ADF/cofilin phosphorylation may be part of the
underlying mechanism for the effects of vortioxetine on structural plasticity (Chen et al., 2016; Waller et al., 2015). To our
knowledge, this is the first report on the effects of an antidepressant on ADF/cofilin. Previous studies demonstrate that modulating cofilin phosphorylation can regulate the size and number of
dendritic spines (Calabrese et al, 2014; Carlisle et al., 2008; Chen
et al., 2007; Foote et al., 2015; Gu et al., 2010). This is consistent
with previous reports that increased Arc/Arg3.1 expression is
associated with increased cofilin phosphorylation (Messaoudi
et al., 2007; Suzuki et al., 2011). How vortioxetine modulates the
phosphorylation of ADF/cofilin is yet to be examined. It is known
that the main kinase phosphorylates ADF/cofilin (LIM domain
kinase 1, LIMK1) and that the main phosphatase that dephosphorylates ADF/cofilin (protein phosphatase slingshot-1 (SSH-1))
can be regulated by PKA (Nadella et al., 2009; Romarowski
et al., 2015) and/or CaMKII (Zhao et al., 2012). It will be interesting to examine which of these possible mechanisms underlies
the effect of vortioxetine on ADF/cofilin phosphorylation.
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Figure 5. Effects of vortioxetine and fluoxetine on gene expression in the frontal cortex of middle-aged mice. Gene expression levels were measured
using quantitative RT-PCR. Levels in young mice were included as an age control. Middle-aged mice had significantly lower mRNA levels of Arc/
Arg3.1 (A) and Fos (B), compared to the young mice. These age-associated reductions were fully reversed by chronic vortioxetine, but not fluoxetine,
treatment. There was no change in the transcript level of the AMPA receptor subunit GluA1 (Gria) in (C), nor the CaMKIIα (Camk2a, in D). There were
n = 10 per group. One-way ANOVA was followed by Dunnett’s comparison at p < 0.05, as compared to VEH-treated middle-aged mice.

AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANOVA: analysis of variance; FLX: fluoxetine; mRNA: messenger ribonucleic acid; RT-PCR: reverse transcriptase polymerase chain reaction; VEH: vehicle; VOR: vortioxetine.

Modulation of AMPA receptor subunit GluA1 phosphorylation provides a mechanism for vortioxetine’s regulation of
functional plasticity (LTP and LTD), which are among the cellular bases critical for memory formation. Results from the
present study raise the possibility that vortioxetine may be
modulating AMPA receptor trafficking. On the one hand, as
vortioxetine increases glutamate neurotransmission (Dale
et al., 2014), it is critical for the system to maintain sensitivity
to additional stimuli, in spite of increased baseline activity via
homeostatic scaling (Davis, 2006). This may be achieved by
increasing Arc/Arg3.1 expression, which can upregulate
the endocytosis of GluA1(Chowdhury et al., 2006); and by
increasing ADF/cofilin phosphorylation, which can reduce the
synaptic membrane surface expression of the AMPA receptor,
independent from its effect on synaptic structure (Gu et al.,
2010; Wang et al., 2013). On the other hand, S845 GluA1
phosphorylation may target the AMPA receptor to cell surface
(Diering et al., 2014; Ehlers, 2000; Esteban et al., 2003; He
et al., 2009) and replenish the AMPA receptor at the synaptic
membrane. Therefore, vortioxetine may be facilitating AMPA
receptor trafficking between synaptic and extra-synaptic
spaces. In addition, vortioxetine may also modulate the
channel activities of the AMPA receptor, as phosphorylation of
GluA1 S845 stabilizes Ca2+ permeable AMPAR on the cell surface (He et al., 2009), and increases the peak open probability
of AMPAR (Banke et al., 2000). The overall effect may be an
increased glutamate-gated current (Roche et al., 1996) and
amplified downstream signal transduction cascades. It will
be interesting to directly measure the distribution of AMPA
receptors at the synaptic surface, as well as the functions of

Arc/Arg3.1-associated endocytosis machinery in response to
vortioxetine in future studies.
The result from the present study provided some evidence
that vortioxetine activates both the PKA and the CaMKII signaling cascades. Vortioxetine seems to activate PKA, as PKAdependent phosphorylation of GluA1 S845 (Roche et al., 1996)
was increased after both acute in vitro and chronic in vivo vortioxetine treatment. In addition, acute vortioxetine increases activation of CaMKII (measured as increased CaMKIIα T-286
phosphorylation), consistent with the effect of increased glutamate neurotransmission. Interestingly, CaMKII/PKC-dependent
phosphorylation of GluA1 at S831 (Tan et al., 1994) was not
altered after either acute in vitro or chronic in vivo vortioxetine
treatment. This may be due to transient changes in S831 phosphorylation that were not detected at the time points assessed in
the current study (Ai et al., 2011). Future studies to directly
measure the PKA and CaMKII activities will be useful to test the
hypothesis that the PKA and CaMKII signaling cascades are
involved in vortioxetine’s mechanism of action. Alternatively,
increased phosphorylation levels of proteins after vortioxetine
treatment may result from down-regulation of phosphatase activities, which also warrants further investigation.
Some age-related changes were observed in the present study.
For example, middle-aged mice had lower levels of neuroplasticity-related molecules, including GluA1 protein (Figure 3), Arc/
Arg3.1 and Fos mRNA (Figure 5) in the frontal cortex. Similar
age-associated changes have been reported in the hippocampus
(Chen et al., 2016; Li et al., 2015a; Newton et al., 2008). It is
interesting that while middle-aged mice had lower GluA1 protein
in synaptosomes, the total GluA1 transcript level was not
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Figure 6. Hypothesized mechanisms for vortioxetine’s upregulation of neuroplasticity. The current study demonstrated increases in Arc/Arg3.1
expression, CamKII activation, GluA1 phosphorylation at S845, and phosphorylation of ADF/cofilin (highlighted with bold black font for in vivo
observations, bold italic purple font for in vitro observations, and bold underlined blue font for both in vivo and in vitro observations). Combined
with prior observed electrophysiological effects, we hypothesize some molecular underlying mechanisms for vortioxetine. Vortioxetine-induced
increase of glutamate neurotransmission leads to upregulations of the Ca2+ and cAMP signaling cascades. These second messengers activate PKA and
CaMKII, and increase the expression of immediate-early genes such as Arc/Arg3.1 via upregulating transcription factors such as CREB. Consequences
of activation of Arc/Arg3.1 expression and second messenger signaling cascades include an increase in growth and maturation of dendritic spines via
inactivation of ADF/cofilin by phosphorylation; an upregulation of AMPA receptor trafficking, including both the removal (via Arc/Arg3.1 and ADF/
cofilin-related mechanisms) and insertion (via PKA phosphorylation) of AMPA receptors; and altered AMPA channel activities. The overall effect is
increased structural and functional neuroplasticity.

ADF: actin-depolymerizing factor; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; cAMP: cyclic adenosine monophosphate; CREB: cAMP response element-binding
protein; PKA: protein kinase A.

different. This may result from a difference in GluA1 subcellular
localization (synaptic versus cytosolic localization), a reduction
in GluA1 protein synthesis, or an increase in GluA1 protein degradation in middle-aged mice. In addition, middle-aged mice
responded to vortioxetine treatment differently compared to
young mice. Even though vortioxetine increased Arc/Arg3.1
expression at the transcript and protein levels, vortioxetine did
not change the phosphorylation levels of cofilin and GluA1 in
middle-aged mice. It will therefore be interesting to investigate if
alternative pathways downstream from Arc/Arg3.1, such as
PSD95 (Soule et al., 2008) and components of the NMDA receptor complex (Husi et al., 2000), may mediate behavioral outcomes following vortioxetine treatment of middle-aged mice (Li
et al., 2015a). These differences may reflect the age-related
changes in synaptic plasticity (Oberman and Pascual-Leone,
2013) that are critical for cognitive and affective functions.
The present study demonstrates that vortioxetine is different
from fluoxetine in terms of effects on neuroplasticity. In contrast
to increased Arc/Arg3.1 and Fos expression in the frontal cortex
by vortioxetine treatment, an equivalent dose of fluoxetine was

ineffective in middle-aged mice. This is consistent with the findings in the hippocampus (Li et al., 2015a). While the brain-derived
neurotrophic factor (BDNF) signaling pathway has been shown to
mediate regional effects of fluoxetine on Arc/Arg3.1 expression in
young male rodents (Alme et al., 2007), vortioxetine does not
increase BDNF at the mRNA level in hippocampal (Li et al.,
2015a) or in frontal cortical (results not shown) homogenate in
middle-aged female mice. It will be interesting to examine the
effects of vortioxetine on BDNF protein levels in different brain
regions. In addition, vortioxetine modulates GluA1 phosphorylation at the PKA site without affecting the total GluA1 levels,
which is different from the effects of fluoxetine (Ampuero et al.,
2010). Differences between vortioxetine and SSRIs (fluoxetine or
escitalopram) in other measures of neuroplasticity have been
reported, such as structural plasticity (Chen et al., 2016; Waller
et al., 2015), functional plasticity (Dale et al., 2014) and neurogenesis (Betry et al., 2015; Guilloux et al., 2013). Direct modulations of 5-HT receptors contribute to the effects of vortioxetine
(Betry et al., 2013; Dale et al., 2014). Therefore, the multimodal
mechanism of action may be essential for vortioxetine’s
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modulation of neuroplasticity. This notion is further supported by
preclinical studies demonstrating that vortioxetine, but not SSRIs,
improved performance of rodents in both cortical- and hippocampal-dependent behavioral tests (Sanchez et al., 2015). We hypothesize that 5-HT3 antagonism may be the key that differentiates
vortioxetine from SSRIs such as fluoxetine.
The current study utilized different experimental systems to
examine the effects of vortioxetine on neuroplasticity related
molecules. For in vivo studies, cortical changes were measured
in young adult and middle aged mice, after chronic dosing
(1 month). For the in vitro study, effects of acute drug treatment
(1 h) were measured in isolated embryonic rat hippocampal neurons. Some effects were observed in both young adult mice and
in cultured neurons: Vortioxetine increased phosphorylation of
GluA1 protein at the S845 residue, without changing the phosphorylation of the S831 residue, nor the total GluA1 protein levels. A hypothetical model of the molecular mechanism of
vortioxetine is proposed, combining results from different experimental systems; however, it should be kept in mind that links
between in vivo and in vitro effects are tentative, and some parts
of the model are experimental system specific.
We hypothesize that vortioxetine increases neuroplasticity via
modulation of multiple molecular targets (Figure 6). Vortioxetine
increases glutamate neurotransmission, likely through a 5-HT3
receptor antagonism-mediated attenuation of GABAergic inhibitory control of glutamate signaling (Dale et al., 2014, 2016; Riga
et al., 2014). This may lead to increased activities of Ca2+ and
cAMP signaling cascades via stimulation of ionotropic and
metabotropic glutamate receptors (Menard et al., 2015), which in
turn increases the expression of immediate-early genes such as
Arc/Arg3.1 and Fos. Consequences of Arc/Arg3.1 activation and
signaling cascades include:
1.
2.

Increased growth and maturation of dendritic spines via
inactivation of ADF/cofilin by phosphorylation; and
Upregulation of AMPA receptor trafficking, including
both the removal (via Arc/Arg3.1- and ADF/cofilinrelated mechanisms) and insertion (via PKA phosphorylation) of AMPA receptors.

The net effect of vortioxetine treatment is increased structural
and functional neuronal plasticity, which may be the underlying
mechanisms for the positive effects of vortioxetine on cognitive
function observed in both pre-clinical and clinical studies (Sanchez
et al., 2015).
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